Keywords
thalassemia
hemoglobins
genetic therapy
blood tansfusion
iron chelating agents
How to Cite
Abstract
Beta-thalassemia is a congenital disorder generally caused by point mutations in the gene that encodes for the synthesis of globin beta chains, which produces an ineffective erythropoiesis phenomenon, and reduces the half-life of erythrocytes in the most severe forms. However, the classification includes forms of thalassemia of various clinical behaviors; from severe forms to asymptomatic forms. Complications are usually associated with the chronic treatment utilized in this disorder, which includes repeated blood transfusions, amongst others. New therapies seek to reduce the adverse effects associated with transfusions, as well as targeting genetic components of the disease.
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The authors keep the copyright and publication rights in the journal the right of the first publication and this possibility to edit, reproduce, distribute, expose and publicly communicate on the magazine's website. Likewise, it assumes the commitment on any litigation or claim related to the rights of intellectual property, exonerating of responsibility to the Science and Health Magazine of the UCIMED. In addition, you can see how they are published in this journal (eg, Include in an institutional repository or publish it in a book) as long as they clearly indicate the work published for the first time in the magazine Science and Health of the UCIMED.